Genzyme's Termeer Says He'd Sell at `Fair Value,' Not Sanofi's $69 a Share
Genzyme’s board hasn’t asked bankers to reach out to other bidders “but that’s quite obviously a logical situation to develop,” Termeer said in a telephone interview today.
Sanofi, France’s largest drugmaker, on Aug. 29 made public an offer to acquire Cambridge, Massachusetts-based Genzyme for about $18.5 billion. Genzyme, the world’s largest maker of medicines for genetic diseases, rejected the bid yesterday, saying it undervalued the company’s pipeline and efforts taken to fix contamination in a Boston manufacturing plant.
“Every company is for sale at some price,” Termeer said in the interview. “The company is not for sale at $69 and we made that clear. What the board needs to see, and what the shareholders deserve, is a fair value of the company.”
Genzyme rose 20 cents to $70.11 as of 5:19 p.m., New York time, in Nasdaq Stock Market composite trading, $1.11 more than Sanofi’s bid. The shares have gained 29 percent since July 22, the last day of trading before the French drugmaker’s interest was reported. Sanofi declined 29 cents to 45.27 euros in Paris trading.
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.